I agree. I understand that people like the thought of a buyout because it means instant reward and an end to the wait. However, as I feel I have expressed on numerous occasions, I don't see it as being in the best interests of NWBO or Linda Powers and the management team. I also seriously doubt that any offer is really going to hit NWBO's potential worth.
Linda Powers has made clear in the past the desire to control NWBO's future and to ensure that DC-Vax is available to the patients who need it. It is not necessarily in BP's interests to have that happen as long as Keytruda and the rest of the swill they push can be sold. BP is not in the business of individualize medicine, they are in the business of pill distribution whether you need the pill or not and whether or not it actually benefits you.
I have asked the question in the past as to what NWBO gets from a buyout. About a year or so ago the answer was expertise and influence in the approval process and to a lesser extent some indicated the belief that Big Pharma could contribute to production and distribution.
If they wanted approval assistance, they should have paired up with someone a year ago. It seems pretty clear that they are happy to go it alone and deal with the somewhat unique, or at least novel, issues the DC-Vax trial offers.
With Sawston and Flaskworks, it is pretty clear that NWBO is at least as capable, and probably far more capable, of producing and distributing DC-Vax as any BP would be or will be in the foreseeable future.
Maybe there will be a partnership but I think a buyout is extremely unlikely. Just my personal, barely-informed thoughts.
